Porcellato I, Menchetti L, Brachelente C, Sforna M, Reginato A, Lepri E, Mechelli L
1 Department of Veterinary Medicine, University of Perugia, Perugia, Italy.
2 CDVet Diagnostic Laboratory, Via Ugo Guattari, Rome, Italy.
Vet Pathol. 2017 Mar;54(2):204-211. doi: 10.1177/0300985816677148. Epub 2016 Dec 22.
Feline injection-site sarcoma (FISS) is an aggressive tumor believed to arise from the proliferation of fibroblasts and myofibroblasts in areas of chronic inflammation, particularly at sites of injection. Local recurrence is frequent after surgical excision. Gelatinases (MMP-2 and MMP-9) and their inhibitor (TIMP-2) are endopeptidases pivotal in extracellular matrix remodeling and therefore in tumor invasiveness. The aim of this study was to investigate the immunohistochemical expression of MMP-2, MMP-9, and TIMP-2 in FISS to assess their usefulness as prognostic factors. Size, soft tissue sarcoma (STS) grading system, depth of infiltration, surgical margins, and Ki-67 index were evaluated as additional prognostic markers. Twenty-four cases of primary FISS were classified according to clinical follow-up as nonrecurrent (NR, n = 14; 58.3%) and recurrent (R, n = 10; 41.7%). MMP-2, MMP-9, and TIMP-2 were variably expressed in the FISS examined, confirming their role in tumor invasiveness, yet they did not show significant differences between the R and NR groups. These results could be due to different tumor stages or to the multiple activities of these enzymes, not limited to ECM remodeling. The immunohistochemical expression of these enzymes considered alone does not seem to be useful as a prognostic marker. STS grading system, depth of infiltration, surgical margins, and Ki-67 index did not relate to recurrence. Instead, the size of the tumor, measured after formalin fixation, with an optimal cutoff of 3.75 cm (accuracy = 86%; P < .05), and the mitotic count, with an optimal cutoff of 20 mitoses/10 HPF (accuracy = 80%; P < .05), could be evaluated as useful prognostic markers.
猫注射部位肉瘤（FISS）是一种侵袭性肿瘤，被认为起源于慢性炎症区域，特别是注射部位的成纤维细胞和肌成纤维细胞的增殖。手术切除后局部复发很常见。明胶酶（MMP-2和MMP-9）及其抑制剂（TIMP-2）是细胞外基质重塑以及肿瘤侵袭性的关键内肽酶。本研究的目的是调查MMP-2、MMP-9和TIMP-2在FISS中的免疫组化表达，以评估它们作为预后因素的效用。将肿瘤大小、软组织肉瘤（STS）分级系统、浸润深度、手术切缘和Ki-67指数作为额外的预后标志物进行评估。根据临床随访，24例原发性FISS被分为非复发性（NR，n = 14；58.3%）和复发性（R，n = 10；41.7%）。在检测的FISS中，MMP-2、MMP-9和TIMP-2呈不同程度表达，证实了它们在肿瘤侵袭性中的作用，但在R组和NR组之间未显示出显著差异。这些结果可能是由于不同的肿瘤分期或这些酶的多种活性，而不仅限于细胞外基质重塑。单独考虑这些酶的免疫组化表达似乎不能作为预后标志物。STS分级系统、浸润深度、手术切缘和Ki-67指数与复发无关。相反，经福尔马林固定后测量的肿瘤大小，最佳截断值为3.75 cm（准确率 = 86%；P < .05），以及有丝分裂计数，最佳截断值为20个有丝分裂/10个高倍视野（HPF）（准确率 = 80%；P < .05），可被评估为有用的预后标志物。
